Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study).
- DOI
- 10.1093/jnci/djae098
- Published
- 2024 Sep 1
- Container
- Journal of the National Cancer Institute
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/jnci/djae098,
title = {Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study).},
author = {Fontana E and Rosen E and Lee EK and Højgaard M and Mettu NB and Lheureux S and Carneiro BA and Cote GM and Carter L and Plummer R and Mahalingam D and Fretland AJ and Schonhoft JD and Silverman IM and Wainszelbaum M and Xu Y and Ulanet D and Koehler M and Yap TA},
year = {2024},
journal = {Journal of the National Cancer Institute},
doi = {10.1093/jnci/djae098},
url = {https://doi.org/10.1093/jnci/djae098}
}RIS
TY - JOUR TI - Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study). AU - Fontana E AU - Rosen E AU - Lee EK AU - Højgaard M AU - Mettu NB AU - Lheureux S AU - Carneiro BA AU - Cote GM AU - Carter L AU - Plummer R AU - Mahalingam D AU - Fretland AJ AU - Schonhoft JD AU - Silverman IM AU - Wainszelbaum M AU - Xu Y AU - Ulanet D AU - Koehler M AU - Yap TA PY - 2024 JO - Journal of the National Cancer Institute DO - 10.1093/jnci/djae098 UR - https://doi.org/10.1093/jnci/djae098 ER -
APA
E, F., E, R., EK, L., M, H., NB, M., S, L., BA, C., GM, C., L, C., R, P., D, M., AJ, F., JD, S., IM, S., M, W., Y, X., D, U., M, K., & TA, Y. (2024). Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study).. Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae098
Source records
- pubmed · retrieved 2026-09-25T19:26:30.745Z